Rasagiline is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor indicated as a monotherapy or adjunctive treatment for Parkinson's disease, where it functions by increasing dopamine availability… Read more













































Rasagiline is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor indicated as a monotherapy or adjunctive treatment for Parkinson's disease, where it functions by increasing dopamine availability in the brain. The compounds in this category serve as critical analytical tools for pharmaceutical laboratories engaged in drug development and quality control. Comprehensive impurity profiling requires high-quality reference standards of process-related impurities and degradation products to ensure the safety and efficacy of the drug substance. Additionally, stable isotope labelled compounds are essential for accurate quantification in complex matrices, serving as reliable internal standards for mass spectrometry-based assays. These materials are fundamental to method validation, stability studies, and routine release testing, supporting analysts in maintaining compliance with stringent regulatory requirements throughout the drug’s lifecycle. By utilizing these precisely characterized reference materials, laboratories can ensure the consistency and performance of their analytical procedures for this important antiparkinsonian agent.